Roche‘s (OTC:RHHBY) Genentech touted positive top-line data today from a Phase II study of its Port Delivery System, an eye implant designed to administer a sustained dose of ranibizumab in patients with wet age-related macular degeneration.
The refillable device, which is roughly the size of a grain of rice, is intended to enable wet-AMD patients to go for months without needing to see an ophthalmologist for treatment. The current standard of care for wet-AMD involves monthly injections of anti-vascular endothelial growth factor therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post Genentech touts positive data for tiny, refillable eye implant appeared first on MassDevice.
from MassDevice https://ift.tt/2LnWcZR
Cap comentari:
Publica un comentari a l'entrada